BioSpace News Archive

Genetown

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD).

June 18, 2024
·
11 min read
Genetown

Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

Haemonetics Corporation, a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device.

June 18, 2024
·
4 min read
Business

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024.

June 18, 2024
·
3 min read
Genetown

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 18, 2024

Stoke Therapeutics, Inc. announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

June 18, 2024
·
2 min read
BioMidwest

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron Inc. announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024.

June 18, 2024
·
7 min read
Biotech Beach

Aptose Announces Results from Annual and Special Meeting of Shareholders - June 18, 2024

Aptose Biosciences Inc. announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024.

June 18, 2024
·
5 min read
Drug Development

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025.

June 18, 2024
·
8 min read
BioMidwest

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Orsini Specialty Pharmacy, and Zevra Therapeutics, Inc. announced that Orsini is now the pharmacy partner for OLPRUVA® for oral suspension.

June 18, 2024
·
7 min read
Drug Development

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Spyre Therapeutics, Inc. today announced that it has initiated dosing of healthy volunteers in its first clinical trial of SPY001, an investigational novel half-life extended anti-α4β7 monoclonal antibody.

June 18, 2024
·
7 min read
Epigenica Unveils Breakthrough Epigenetics Platform, Launches First Commercial ChIP-seq Kit for High-throughput, Multiplex Genome-wide Profiling

Epigenica today unveiled its EpiFinder™ Platform with a patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology and launched EpiFinder Genome for comprehensive genome-wide profiling.

June 18, 2024
·
4 min read